Cleveland Clinic unveils list of top 10 medical innovations for 2022
The Cleveland Clinic gave a glimpse into the future with its list of the top 10 medical innovations for 2022.
The list is an annual exercise by the Clinic, which consults with an expert panel of clinicians and researchers to compile the innovations highlighted. (A description of the selection process and criteria is here.) D. Geoffrey Vince, Ph.D., executive director of innovations and chair of biomedical engineering at the clinic, said in a statement that the Top 10 Medical Innovations program “was launched to share their insights with the entire healthcare community, and year after year, our professionals continue to successfully predict advancements in devices, technologies, topics and therapies. . »
Here’s the list for 2022, ranked “in order of anticipated importance,” according to the Clinic:
1. Next generation mRNA vaccinology
“Advances in RNA generation, purification and cellular delivery have enabled the development of mRNA vaccines in a wide range of applications, such as cancer and Zika virus infection,” the clinic said. . “The technology is cost-effective, relatively simple to manufacture, and elicits immunity in new ways. Additionally, the emergence of the COVID-19 pandemic has demonstrated that the world needs the rapid development of a vaccine that can be deployed worldwide… This landscape-changing technology has the potential to be used to quickly and effectively manage some of the most challenging diseases in healthcare.”
2. PSMA-targeted therapy in prostate cancer
Each year, according to the clinic, more than 200,000 American men are diagnosed with prostate cancer. PSMA, an antigen present in high levels on the surface of prostate cancer cells, is a potential biomarker of the disease. “When detected early by PET PSMA scans, recurrent prostate cancer can be treated with a targeted approach with stereotactic body radiation therapy, surgery, and/or systemic therapy in a personalized manner,” according to the clinic.
3. New treatment for LDL reduction
“High levels of blood cholesterol, particularly low-density lipoprotein (LDL-C), are known to be a significant contributor to cardiovascular disease,” according to the clinic. “Inclisiran is an injectable small interfering RNA that targets the protein PCSK9. Unlike statins, it requires infrequent administration (twice a year) and provides effective and sustained lowering of LDL-C in conjunction with statins. Its Prolonged effect may help relieve medication non-adherence, one of the main causes of failure to lower cholesterol levels.”
4. New drug for the treatment of type 2 diabetes
In the United States, 1 in 10 people have diabetes, which affects how the body converts food into energy. One potential therapy, according to the clinic, “is a once-weekly injectable dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide (GLP-1) receptor agonist that aims to control blood sugar.”
5. Revolutionary treatment for postpartum depression
In 2019, the U.S. Food and Drug Administration “approved an intravenous infusion therapy designed to specifically treat postpartum depression,” the clinic said. “This new therapy, delivered around the clock for 60 hours, uses a neurosteroid to control the brain’s response to stress. This treatment design is revolutionary because it targets signaling thought to be deficient in hormone-responsive postpartum depression. What’s more, this treatment seems to show benefits very quickly, whereas traditional antidepressants typically take two to four weeks to have a significant effect.”
6. Targeted drugs for hypertrophic cardiomyopathy
The clinic said that for decades, “clinicians have only been able to treat patients’ symptoms of hypertrophic cardiomyopathy (HCM) – using drugs developed to treat other heart conditions – with limited effectiveness. … A new treatment, however, is working to reduce the root cause of the problem in many patients.A first-class drug specifically targets the heart muscle to reduce abnormal contractions caused by genetic variants that put the heart in overdrive.The FDA has set a target action date for this therapy of April 28.
7. Non-hormonal alternatives for menopause
A new group of non-hormonal drugs, called NK3R antagonists, “have emerged as a viable alternative” to traditional hormone therapy, the clinic said. “These drugs disrupt a signaling pathway in the brain that has been linked to the development of hot flashes and has shown promise in clinical trials to relieve moderate to severe menopausal hot flashes as effectively as hormones.”
8. Implantable for severe paralysis
The clinic said about one in 50 Americans, or 5.4 million people, have some form of paralysis. “Recently, a team offered new hope to these patients by leveraging implanted brain-computer interface technology to recover lost motor control and allow patients to control digital devices,” according to the clinic. “The technology uses implanted electrodes to collect movement signals from the brain and decode them into movement commands.”
9. AI for early detection of sepsis
Sepsis is a severe inflammatory response to infection and one of the leading causes of hospitalization and death worldwide. The clinic said that artificial intelligence “has emerged as a new tool that can help detect sepsis early. Using AI algorithms, the tool detects several key risk factors in real time by monitoring patients’ electronic medical records as physicians enter information.”
10. Predictive analysis and hypertension
“Using machine learning, a type of artificial intelligence, physicians are able to better select more effective drugs, drug combinations, and dosages to improve hypertension control,” the clinic said. “AI will also allow physicians to predict cardiovascular morbidities and focus on interventions before they occur.”
Go here for a full description of each innovation.